爱迪注射液联合化学治疗中晚期肺癌的临床研究  

Clinical Study on Aidi Injection Combined Chemotherapy for Treating Middle and Late Stage Lung Cancer

作　　者：徐滢[1] 张永军[1] 芦柏震[1] 

机构地区：[1]浙江省肿瘤医院,浙江杭州310022

出　　处：《中国药业》2012年第23期56-57,共2页China Pharmaceuticals

摘　　要：目的比较爱迪注射液联合化学治疗与单纯化学治疗对中晚期肺癌的疗效、不良反应及Karnofsky评分。方法将66例Ⅲb～Ⅳ期患者随机分为对照组及治疗组,对照组采用GP(gemcitabine+cisplatin)方案治疗,治疗组采用GP方案+爱迪注射液治疗,连续4周期,比较两组的疗效、不良反应及Karnofsky评分。结果两组有效率均为48.49%,但疾病控制率治疗组(90.91%)明显高于对照组(78.79%),不良反应发生率治疗组较对照组低(P<0.05)。结论爱迪注射液联合化学治疗具有增效减毒作用,且可改善患者生活质量。Objective To compare the effects, adverse reactions and Karnofsky scores between Aidi Injection combined chemotherapy and simple chemotherapy in the treatment of middle and late stage lung cancer. Methods Sixty- six cases of lung cancer with Ⅲb～Ⅳ stage were enrolled and divided into 2 groups. The treatment group adopted the gemcitabine and cisplatin（GP） scheme plus Aidi Injection and the control group was treated with the GP scheme alone. After continuous 4 treatment cycles, the curative effects, adverse reactions and Karnofsky scores were compared between the two groups. Results The effective rates were same in the two groups （48.49%）. But, the disease control rate was 90. 91% in the treatment group, which was obviously higher than 78.79% in the control group. Furthermore, the treatment group had lower adverse reactions than the control group with statistical difference（P 〈 0.05）. Conclusion Aidi Injection combined chemotherapy has the synergy and attenuation effect, and improves the life quality of patients.

关 键 词：爱迪注射液 中晚期肺癌 疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]